Premium
Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men—A Randomized Controlled Trial
Author(s) -
Kruse Michael,
Kemper Margrit,
Gancheva Sofiya,
Osterhoff Martin,
Dannenberger Dirk,
Markgraf Daniel,
Machann Jürgen,
Hierholzer Johannes,
Roden Michael,
Pfeiffer Andreas F. H.
Publication year - 2020
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.202000419
Subject(s) - medicine , steatosis , fatty liver , endocrinology , polyunsaturated fatty acid , lipid metabolism , obesity , fatty acid , chemistry , biochemistry , disease
Scope Effective treatment for obesity associated non‐alcoholic fatty liver disease (NAFLD) is limited. Dietary supplementation of n‐3 polyunsaturated fatty acids, specifically alpha linolenic acid (ALA), can resolve intrahepatic lipid content (IHL). This study investigates the effect of daily supplementation of either refined rapeseed (RA), containing high amounts of ALA, or refined olive (OL) oil on IHL and glucose metabolism in NAFLD patients. Methods and results 27 obese men consumed an isocaloric diet including either 50 g of RA or OL daily for 8 weeks. Hepatic proton magnetic resonance spectroscopy, hyperinsulinemic–euglycemic clamp studies and blood tests are performed before and at the end of the study. At 8 weeks a significant reduction in IHL is observed for RA (13.1 ± 1.6 before versus 11.1 ± 1.6% after intervention) versus OL (13.3 ± 2.5 before versus 15.7 ± 2.7% after intervention). For RA, a 21% reduction ( P < 0.02) in serum free fatty acids (FFA) and a 1.68‐fold increase ( P = 0.03) of serum interleukin‐6 (IL‐6) is observed after 8 weeks. Conclusion RA has a beneficial effect on hepatic lipid metabolism as shown by reduced IHL and serum FFA. RA induced IL‐6 production seems to be liver protective confirming previous results.